TROG Cancer Research
Members Login   CQMS Login

Breast cancer trials in development

Our breast cancer trials focus on the effects and benefits of radiation therapy as a treatment.

TD 17.08 (TAILOR RT) - The aim of this study is to reduce over treatment of low risk breast cancer by identifying markers (in the patients’ blood test) to identify a group of patients that may not require radiotherapy.    

Primary Sponsor: Canadian Cancer Trials Group (CCTG)
Collaborating Groups: TROG


TD 17.07 (SKAGEN Trial 1) - This study aims to investigate the difference in late radiation morbidity between hypofractionated and normofractionated loco-regional breast irradiation irrespective of mastectomy or lumpectomy. 

Primary Sponsor: Danish Breast Cancer Cooperative Group (DBCG)
Collaborating Groups: TROG


More about breast cancer and our trials

What is breast cancer?

Breast cancer is the result of abnormal cells grouping together and growing uncontrollably. There are many different types of breast cancer, and can be treated depending on the stage and type of cancer.

What is a clinical trial?

A clinical trial is a research study which explores whether certain medical treatments are effective in preventing, detecting, treating or managing a disease or medical condition. Our breast cancer research trials help us develop a better understanding of treating breast cancer and improving treatments.

How do I participate in TROG trials?

You can discuss your suitability for a trial with your doctor or oncologist, or you can see more information below on breast cancer trials and contact the nearest participating centre.

About TROG's work with breast cancer research

One of our trials (TROG 03.05 MA.20) was revolutionary in the way breast cancer has been treated. Radiotherapy for breast cancer is a common treatment method, and the results of our trial demonstrated that radiotherapy to the lymph nodes was more effective in treating cancer than radiation to the breast only. Results of this trial proved that lymph node radiation was effective in decreasing the risk of cancer returning to other organs in the body.




 

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.